Donepezil News and Research

RSS

Donepezil is a drug that is used to treat Alzheimer disease and is being studied in the treatment of side effects caused by radiation therapy to the brain. It is a type of cholinesterase inhibitor.

Vanderbilt launches $13 million trial to test repurposed drugs for Rett syndrome

Vanderbilt University Medical Center received a $13 million Department of Defense grant to lead a multisite clinical trial that will evaluate repurposed FDA-approved drugs as treatment options for patients with Rett syndrome.

16 Jan 2024

Pharmacogenomics holds promise for personalized dementia therapies

Pharmacogenomics-based studies in the research for personalized therapeutics for dementia

8 Nov 2023

Researchers discover new spiroindolin-1,2-diazepine derivatives with anti-Alzheimer therapeutic potential

In a recent study, researchers designed substituted spiro indolin-1,2-diazepine derivatives '5a–v' with cholinesterase inhibitory activities as anti-Alzheimer's disease agents.

31 Jul 2023

A scientific statement from the American Heart and Stroke Association on the prevalence, diagnosis, and management of poststroke cognitive impairment

Researchers reviewed the incidence, prevalence, diagnosis, and management of post-stroke cognitive impairment.

3 May 2023

Exploring the neuroprotective potential of cell-penetrating peptides, extracellular vesicles, and micro ribonucleic acids

In a recent review published in Biomedicines, researchers explored extracellular vesicles (EVs), cell-penetrating peptides (CPPs), and micro ribonucleic acids (miRNAs) as therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD).

1 Mar 2023

Utilizing marine sources to extract DHA to treat Alzheimer’s

The anti-neurodegenerative effects of docosahexaenoic acid (DHA) and DHA-rich phospholipids (DH-PL) derived from fisheries and aquaculture byproducts.

15 Nov 2022

Delay in consciousness in severe cases of COVID-19 may be caused by neural hibernation

An article published in the journal PNAS provides a conceptual analysis to interpret the brain state of coronavirus disease 2019 (COVID-19) patients experiencing prolonged recovery of consciousness.

10 Nov 2022

Influenza vaccination may provide protective effect against Alzheimer’s disease

Researchers compared Alzheimer's Disease development risks among recipients and non-recipients of intramuscularly administered influenza vaccines.

5 Jul 2022

Study elucidates the molecular mechanisms of acetylcholine for learning and memory

Acetylcholine (ACh) is a neuromodulator with a central role in aversive learning-;rapid conditioning to unpleasant smell, taste, or touch.

28 Jun 2022

Patients divided over Alzheimer’s drug: Is it a ‘risk I’m willing to take’ or just a ‘magic pill’?

If you listen to the nation's largest Alzheimer's disease advocacy organizations, you might think everyone living with Alzheimer's wants unfettered access to Aduhelm, a controversial new treatment.

7 Mar 2022

LSL60101 compound improves cognitive deficit in murine models with Alzheimer’s

The LSL60101 compound, a specific ligand of the I2-IR receptors in the brain, could shed light on the development of future strategies against Alzheimer's disease.

29 Jun 2021

Study shows persisting cognitive benefits of common Alzheimer’s treatment

Cholinesterase inhibitors are a group of drugs recommended for the treatment of Alzheimer's disease, but their effects on cognition have been debated and few studies have investigated their long-term effects.

25 Mar 2021

Study examines the side effects of Alzheimer's disease dementia drugs

In a first of its kind study, a University of Houston researcher is examining two common drugs used for dementia in patients with Alzheimer's disease to determine the extent to which they don't mix well together and cause a cascading event of side effects, prompting the need for even more medications.

3 Sep 2020

Insufficient evidence for cognitive efficacy of drug treatments in multiple sclerosis

Researchers at Kessler Foundation conducted a comprehensive review of pharmacologic agents used in the treatment of multiple sclerosis, seeking evidence for efficacy for the cognitive dysfunction experienced by more than half of affected individuals.

17 Jun 2020

Increase in out-of-pocket costs associated with lower adherence to neurologic medications

As out-of-pocket costs go up for drugs for the neurologic disorders Alzheimer's disease, peripheral neuropathy and Parkinson's disease, people are less likely to take the drugs as often as their doctors prescribed, according to a study funded by the American Academy of Neurology and published in the February 19, 2020, online issue of Neurology, the medical journal of the American Academy of Neurology.

19 Feb 2020

World Alzheimer’s Day 2019: A timely reminder of urgent need for new drugs to tackle disease

As World Alzheimer’s Day 2019 approaches (21 September), with the aim this year of raising global awareness and understanding of the stigma, stereotypes and myths that surround a dementia diagnosis;

17 Sep 2019

Alzheimer's drug associated with two-fold higher risk of hospitalization for rhabdomyolysis

A drug commonly used to manage symptoms of Alzheimer disease and other dementias -- donepezil -- is associated with a two-fold higher risk of hospital admission for rhabdomyolysis, a painful condition of muscle breakdown, compared with several other cholinesterase inhibitors, found a study in CMAJ.

16 Sep 2019

Alzheimer's drug reverses brain damage in rats exposed to alcohol during adolescence

A drug used to slow cognitive decline in adults with Alzheimer's disease appears to reverse brain inflammation and neuron damage in rats exposed to alcohol during adolescence.

20 Aug 2019

Chemotherapy may increase survival for advanced colon cancer patients with dementia, study suggests

A pre-existing diagnosis of dementia was associated with increased risk of death for older patients with advanced colon cancer; however, some of the effects of dementia on survival could be mediated by receipt of chemotherapy.

22 Sep 2017

Researchers explore patient adherence, tolerability to class of Alzheimer's drugs

Researchers from the Indiana University Center for Aging Research and the Regenstrief Institute have performed the first study conducted in the United States under real-world conditions comparing patient adherence and tolerability to a class of drugs known as cholinesterase inhibitors.

11 Apr 2017